Scynexis
Price & Volume
Stats
See more52W Range | $0.56-$1.49 |
Market Cap | $28.4M |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $2.9M |
Revenue Growth (YoY) | -49.4% |
Gross Profit (12 Mos) | $2.9M |
Diluted EPS | -$0.51 |
News
See moreYahoo Finance • 10 days ago
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Yahoo Finance • 12 days ago
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
Yahoo Finance • 24 days ago
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Yahoo Finance • last month
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
About
CEO | Dr. David Gonzalez Angulo M.D. |
Address | 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 28 |
